Stakeholders’ Education | Corporate Governance Research | Corporate Governance Score | Proxy Advisory STAKEHOLDERS EMPOWERMENT SERVICES 1 | P AGE SECTOR: CHEMICALS REPORTING DATE: 14 TH AUGUST, 2017 STERLING BIOTECH LTD. www.sterlingbiotech.in Sterling Biotech Ltd. NSE Code - STERLINBIO TABLE 1 - MARKET DATA (STANDALONE) (AS ON 10 TH AUGUST, 2017) Sector - Chemicals NSE Market Price (`) 3.65 NSE Market Cap. (₹ Cr.) 100.16 Face Value (`) 1.00 Equity (` Cr.) 27.22 Business Group - Sandesara 52 week High/Low (₹) 6.80/3.25 Net worth (₹ Cr.) * 1,476.62 Year of Incorporation - 1985 TTM P/E (TTM) N.A. Traded Volume (Shares) 190,682 TTM P/BV 0.08 Traded Volume (lacs) 6.96 Registered Office - Source - Capitaline, TTM - Trailing Twelve Month, N.A -Not Applicable *As on 30 th September, 2016 43, Atlanta Building, COMPANY BACKGROUND Nariman Point, Sterling Biotech Limited (SBL) was incorporated in 23 rd March of the year 1985 in Mumbai as Pluto Exports & Consultants Limited and obtained its Certificate of Commencement of Business in 19 th April of the same year 1985. SBL is engaged in producing pharmaceutical and nutraceutical gelatin in India and Asia. Additionally, Sterling sells dicalcium phosphate (DCP), a by-product of the gelatin manufacturing process, to poultry-feed and fertilizer industry in India. Sterling began its operations as a trading company, changed its focus to the manufacture of tea in the year 1991 and further changed its name to Sterling Tea and Industries Limited in 24 th June of the year 1991. Its name was subsequently changed to Sterling Biotech Limited. Mumbai – 400 021, Maharashtra Company Website: www.sterlingbiotech.in Revenue and Profit Performance The revenue of the Company decreased from ₹ 108.02 crores to ₹ 87.61 crores from quarter ending Sep’15 to quarter ending Sep’16. The Company made a loss of ₹ 109.51 crores in quarter ending Sep’16 vis-a-vis making a loss of ₹ 94.21 crores in quarter ending Sep’15. Source: Moneycontrol Performance vis-à-vis Market TABLE 2- Returns 1-m 3-m 6-m 12-m Sterling Biotech Ltd -14.12% -30.14% -17.98% -5.19% Nifty -0.72% 3.00% 12.56% 13.63% Nifty Pharma -13.79% -20.08% -16.02% -25.45% Source: Capitaline/ NSE 0.00 0.50 1.00 1.50 2.00 Aug 16 Oct 16 Dec 16 Feb 17 Apr 17 Jun 17 Sterling Biotech Ltd NIFTY NIFTY PHARMA 87.61 116.20 108.02 -109.51 -91.85 -94.21 -150 -100 -50 0 50 100 150 Sep'16 Mar'16 Sep'15 Quarterly revenue and Profit (₹ CRORE) Revenue Profit
8
Embed
STAKEHOLDERS EMPOWERMENT SERVICES STERLING … · STAKEHOLDERS EMPOWERMENT SERVICES 3 | P A G E ECTOR: CHEMICALS THREPORTING DATE 14 AUGUST, 2017 STERLING BIOTECH LTD. TABLE 5 - FINANCIAL
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Only publicly available data has been used while making the factsheet. Our data sources include: BSE, NSE, SEBI, Capitaline, Moneycontrol, Businessweek, Reuters, Annual Reports, IPO Documents and Company Website.
Analyst Certification
The analysts involved in development of this factsheet certify that no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the contents of this factsheet.
Disclaimer
While SES has made every effort and has exercised due skill, care and diligence in compiling this factsheet based on publicly available information, it neither guarantees its accuracy, completeness or usefulness, nor assumes any liability whatsoever for any consequence from its use. This factsheet does not have any approval, express or implied, from any authority, nor is it required to have such approval. The users are strongly advised to exercise due diligence while using this factsheet. This factsheet in no manner constitutes an offer, solicitation or advice to buy or sell securities, nor solicits votes or proxies on behalf of any party. SES, which is a not-for-profit Initiative or its staff, has no financial interest in the companies covered in this factsheet except what is disclosed on its website. The factsheet is released in India and SES has ensured that it is in accordance with Indian laws. Person resident outside India shall ensure that laws in their country are not violated while using this factsheet; SES shall not be responsible for any such violation. All disputes subject to jurisdiction of High Court of Bombay, Mumbai.
SEBI Reg. No. INH000000016
This factsheet or any portion hereof may not be reprinted, sold, reproduced or redistributed without the written consent of Stakeholders Empowerment Services